Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial

BACKGROUND: We report results from a phase II randomised placebo-controlled trial assessing zibotentan, a highly selective endothelin receptor antagonist (ERA), in chronic kidney disease (CKD) secondary to systemic sclerosis (SSc). METHODS: This trial included three sub-studies: ZEBRA 1—a randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Stern, Edward P., Host, Lauren V., Wanjiku, Ivy, Escott, K. Jane, Gilmour, Peter S., Ochiel, Rachel, Unwin, Robert, Burns, Aine, Ong, Voon H., Cadiou, Helen, O’Keeffe, Aidan G., Denton, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158153/
https://www.ncbi.nlm.nih.gov/pubmed/35650639
http://dx.doi.org/10.1186/s13075-022-02818-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158153/
https://www.ncbi.nlm.nih.gov/pubmed/35650639
http://dx.doi.org/10.1186/s13075-022-02818-6

Ejemplares similares